State Key Laboratory for Cellular Stress Biology, School of Life Sciences, Xiamen University, Fujian 361005, China.
Biochem J. 2012 Aug 15;446(1):79-87. doi: 10.1042/BJ20120726.
Retinoids display anti-tumour activity on various cancer cells and therefore have been used as important therapeutic agents. However, adverse side effects and RA (retinoic acid) resistance limit further development and clinical application of retinoid-based therapeutic agents. We report in the present paper the identification of a natural marine product that activates RARs (RA receptors) with a chemical structure distinct from retinoids by high-throughput compound library screening. Luffariellolide was uncovered as a novel RAR agonist by inducing co-activator binding to these receptors in vitro, further inhibiting cell growth and regulating RAR target genes in various cancer cells. Structural and molecular studies unravelled a unique binding mode of this natural ligand to RARs with an unexpected covalent modification on the RAR. Functional characterization further revealed that luffariellolide displays chemotherapeutic potentials for overcoming RA resistance in colon cancer cells, suggesting that luffariellolide may represent a unique template for designing novel non-retinoid compounds with advantages over current RA drugs.
维甲酸在各种癌细胞上显示出抗肿瘤活性,因此被用作重要的治疗剂。然而,不良反应和 RA(视黄酸)耐药性限制了基于维甲酸的治疗剂的进一步发展和临床应用。我们在本文中报道了通过高通量化合物文库筛选,发现了一种具有与维甲酸不同化学结构的天然海洋产物,它能激活 RAR(视黄酸受体)。通过在体外诱导共激活剂与这些受体结合,luffariellolide 被揭示为一种新型的 RAR 激动剂,进一步抑制各种癌细胞的生长和调节 RAR 靶基因。结构和分子研究揭示了这种天然配体与 RAR 结合的独特结合模式,在 RAR 上存在意想不到的共价修饰。功能表征进一步表明,luffariellolide 具有克服结肠癌中 RA 耐药性的化疗潜力,这表明 luffariellolide 可能代表一种独特的模板,用于设计具有优于现有 RA 药物优势的新型非维甲酸化合物。